The Food and Drug Administration accepted for review Dynavax Technologies Corp.'s (Nasdaq: DVAX) responses to the FDA's Complete Response Letter for the Biologics License Application for HEPLISAV-B. The stock price surged $2.40 to close at $6.90.
FDA accepts Dynavax's responses
March 01, 2017 at 16:42 PM EST
